AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01180842 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Yoga treatment program
Description: yoga program designed specifically for the patient with CF
Study NCT02332096 — intervention group
Intervention type: DEVICE
Intervention: Home Sleep Testing Device
Description: Patients will undergo obstructive sleep apnea screening with a FDA approved home sleep testing device.
Study NCT03258905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grounding enhanced app
Description: A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
Study NCT03258905 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Grounding text-only app
Description: A mobile app that uses the Seeking Safety grounding chapter content in text format only
Study NCT02589678 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Tdap - IPV Vaccine
Description: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine (0.5 ml) will be administered intramuscularly.
Study NCT02589678 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: MMR Vaccine
Description: A live attenuated virus vaccine against measles, mumps and rubella (0.5 ml) will be administered intramuscularly.
Study NCT01598688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection immediately after interrupting CSA infusion
Description: Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL.
Study NCT01598688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection five minutes after interrupting CSA infusion
Description: Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL.
Study NCT02366455 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of the length of the right main stem bronchus
Description: Measurement of the length of the right main stem bronchus on CT-Scan
Study NCT02366455 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of the right upper lobe bronchus antero-posterior angulation
Description: Measurement of the right upper lobe bronchus antero-posterior angulation on CT-Scan
Study NCT04032847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATL001
Description: ATL001 infusion
Study NCT02665806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Description: intranasal ciclesonide spray 200 µg once daily
Study NCT04032847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Checkpoint inhibitor
Study NCT02855632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 7 days after first hysteroscopic adhesiolysis, G-CSF will be injected into the uterine cavity after balloon removing.
Study NCT01359735 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HP802-247
Description: High dose HP 802-247, applied at each visit (Week 1-13) or until healed
Study NCT02855632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
Study NCT02855632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hormone therapy
Description: In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
Study NCT01359735 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bacitracin Ointment
Description: One dose of Bacitracin ointment consists of 50 units/1 gram. This will be applied daily for 12 weeks (or until healed).
Study NCT02040597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone/Formoterol/Glycopyrrolate
Study NCT02855632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hormone therapy
Description: In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
Study NCT02855632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cook balloon
Description: At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the device was removed after 7 days.
Study NCT02665806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: fluticasone propionate aqueous nasal spray 200 µg twice a day
Study NCT04533971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy
Description: The WBC procedure consisted of 2-3 min walk in the cryogenic chamber at -110℃. Immediately before the WBC procedures, the patients were provided with a special treatment suit, they were instructed as to how to protect the parts of the body that are particularly vulnerable to frostbite, on the proper way of moving and breathing during the treatment. Excluding Saturdays and Sundays, the WBC treatments were performed daily for the next four weeks. Each time after the WBC the subjects participated in 15-minute kinesitherapy exercises conducted in groups of 5-6 people. The exercises were of general improvement nature and took into account the mobility of the subjects.
Study NCT03978299 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Positive Prostate-Specific Antigen test result
Description: Positive PSA test result as part of opportunistic screening or due to the presence of symptoms suggestive of disease.
Study NCT04968314 — intervention group
Intervention type: BEHAVIORAL
Intervention: Chicago Parent Program
Description: Chicago Parent Program (ChiPP) is a 12-session group-based parenting skills program
Study NCT03990909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acids
Description: 60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to21days (42 total drinks).
Study NCT03990909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice Protein
Description: 60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
Study NCT03990909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: 60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
Study NCT02855632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cook balloon
Description: At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the device was removed after 7 days.
Study NCT00543439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moroctocog alfa (AF-CC)
Description: On-demand therapy for 6 months, followed by routine prophylaxis 25 IU/kg, administered every other day for 1 year.
Study NCT00543439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moroctocog alfa (AF-CC)
Description: Routine prophylaxis crossover:~45 IU/kg, administered 2 times a week for 1 year followed by 25 IU/kg administered every other day for 1 year, or, 25 IU/kg, administered every other day for 1 year, followed by 45 IU/kg, administered 2 times a week for 1 year.
Study NCT03017599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20-gauge ProCore FNB needle
Description: The investigators will prospectively collect data base including patients who underwent EUS-guided biopsy with the 20-gauge ProCore histology needle for the evaluation of Pancreatic solid mass.~EUS procedures will be performed under sedation with linear echoendoscopes. Once the lesion will be penetrated, the stylet will be removed, and suction will be applied for 10 to 20 seconds by using a 10-ml syringe while moving the needle to and fro. All samples will processed at the pathology departments for histological analysis with documentation.
Study NCT01559818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM-101
Description: IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
Study NCT03494205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urtica comp. gel
Description: Urtica comp. gel is a Swissmedic registered medication. The scope of application of Urtica comp. is an imbalanced, affected process of skin-regeneration, in particular when stemming from an overdose of heat or light.~It is applied in first and second-degree burn and scalding, sunburn, allergic and hyperergic (excessive) skin conditions (dermatoses), insect bites, abrasions and ulcers.
Study NCT03494205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: institutional standard skin care Excipial-Hydrolotion
Description: The institutional standard skin care Excipial-Hydrolotion is available to all patients
Study NCT03346031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: music therapy
Description: patients will listen to music with an MP3 headset
Study NCT04917679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag plus diacerein
Description: In the combination group, eltrombopag will be administered orally at an initial dose of 75mg daily for 14 days, and diacerein will be given orally at an initial dose of 50mg bid concomitantly for 14 days (D1-D14). During treatment period, treating physicians will modify the dosage of trial treatment to maintain participants' platelet count at the range of 50 - 150 × 10\^9/L as follows: (1) if platelet count is less than 150 × 10\^9/L, continue the original treatment (eltrombopag 75mg daily plus diacerein 50mg bid); (2) if platelet count is between 150 × 10\^9/L to 250 × 10\^9/L, the treatment will be modified to eltrombopag 50mg daily plus diacerein 50mg bid; (3) if platelet count is over 250 × 10\^9/L, original treatment (both eltrombopag and diacerein) need to be stopped, and platelet count should be reexamined every other day, and the treatment (eltrombopag 50mg daily plus diacerein 50mg bid ) will be restarted until platelet count is below 100 × 10\^9/L.
Study NCT04917679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eltrombopag
Description: In the monotherapy group, eltrombopag also will be administered orally at an initial dose of 75mg daily for 14 days (D1-D14), and the individualized dosage could be modified by treating physicians to maintain participants' platelet count between 50 × 10\^9/L to 150 × 10\^9/L.
Study NCT04466774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dip Home-Based Dipstick Analyzer
Description: The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures six urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
Study NCT03615157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation
Description: Patients will be submitted to a twelve-week combined exercise program of aerobic and peripheral muscle training. They will be randomized in two groups: Home-based and Supervised.
Study NCT03615157 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise rehabilitation
Description: Patients will be submitted to a twelve-week combined exercise program of aerobic and peripheral muscle training. They will be randomized in two groups: Home-based and Supervised.
Study NCT04511689 — intervention group
Intervention type: DEVICE
Intervention: gene-activated bone substitute mixed with autobone
Description: gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone
Study NCT02271386 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Supporting Practice for ADHD (SPA)
Description: The SPA intervention will last for 8 months for each study arm (first 8 months of the study for the intervention group, last 8 months for the control group). The intervention includes 3 components: 1) a series of web-based educational presentations to provide education to providers about evidence-based practice for managing ADHD and strategies for promoting effective communication with families 2) Collaborative consultation designed to address clinical issues arising in practice will be provided by members of the study team.~3) Providers will be given systematic performance feedback with regard to their use of evidence-based practices for ADHD every 2 months during the 8-month intervention period.
Study NCT02271386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Practice for ADHD (SPA)
Description: The SPA intervention will last for 8 months for each study arm (first 8 months of the study for the intervention group, last 8 months for the control group). The intervention includes 3 components: 1) a series of web-based educational presentations to provide education to providers about evidence-based practice for managing ADHD and strategies for promoting effective communication with families 2) Collaborative consultation designed to address clinical issues arising in practice will be provided by members of the study team.~3) Providers will be given systematic performance feedback with regard to their use of evidence-based practices for ADHD every 2 months during the 8-month intervention period.
Study NCT00058266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Description: Given orally
Study NCT00058266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo surgery
Study NCT04466774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urine analysis predicate device for professional user
Description: Results of the experimental HBDA device will be compared to the results of the predicate device tested by a professional user.
Study NCT02314273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-11
Description: patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL
Study NCT02649608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.04 mg Lu AE04621
Description: 0.04 mg dose group
Study NCT02649608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.08 mg Lu AE04621
Description: 0.08mg dose group
Study NCT02649608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2 mg Lu AE04621
Description: 0.2 mg dose group
Study NCT02649608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4 mg Lu AE04621
Description: 0.4 mg dose group
Study NCT02649608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6 mg Lu AE04621
Description: 0.6 mg dose group
Study NCT02649608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8 mg Lu AE04621
Description: 0.8 mg dose group
Study NCT02649608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 mg Lu AE04621
Description: 1.0 mg dose group
Study NCT02649608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.2 mg Lu AE04621
Description: 1.2 mg dose group
Study NCT01612702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg intravenous administration
Study NCT02572180 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMG-based biofeedback training
Study NCT02572180 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NIRS-based neurofeedback training
Study NCT03956667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live Music
Description: Musicians from Cascade Music will provide recruited participants in the experimental arm with high-quality calming, distracting music during their Emergency Department procedure.
Study NCT00558519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00558519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00558519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Study NCT00558519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00558519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00558519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Study NCT00558519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00558519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Study NCT00558519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Study NCT00558519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00558519 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02359084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Navigation
Study NCT02359084 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care Management
Study NCT03140085 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PYO Phage
Description: Intravescial instillation
Study NCT03140085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Oral application
Study NCT03140085 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile bacteriology media
Description: Sterile bacteriology media, with identical color as bacteriophage preparation
Study NCT04472182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride varnish with xylitol coated calcium and phosphate
Description: Fluoride varnish with xylitol coated calcium and phosphate
Study NCT04472182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride varnish with xylitol coated calcium and phosphate
Description: Fluoride varnish with xylitol coated calcium and phosphate
Study NCT02522754 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Protesomal Vaccine
Description: Intranasal vaccine Protesomal Vaccine
Study NCT02021279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MatriStem Pelvic Floor Matrix
Study NCT02021279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: native tissue repair
Study NCT01523678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
Study NCT04092660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change Intervention Based on Health Action Process Approach Model
Description: The Behaviour change intervention based on the Health Action Process Approach model entails delivering interventions in a staged manner. Following are the intervention that will be delivered along with the time point of the delivery.~1. Health Pamphlet at the initial screening~2. Sleep Apnoea video highlighting the negative consequences at the day of the fitting of the appliance~3. Counseling involving motivational interviewing for both the participant and the participant's partner at the day of fitting of the appliance and follow up visits.~4. Booster phone calls in between the follow-up visits
Study NCT04092660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Appliance (MAA) or Anti-snoring mouth guard
Description: Patients with mild-to-moderate sleep apnoea are treated with Mandibular Advancement Appliances \[MAA\] also known as Anti-snoring mouth guards or Oral appliances. These are best made to fit and use the teeth to hold them in place during sleep. They work by moving (in a gradual fashion) the bottom jaw forward, opening the airway at the back of the throat.~Both the arms- Intervention arm and Standardized arm will be given the anti-snoring mouth guard. The usage of the device will be measured subjectively by providing a sleep diary to the participants to record the hour of the usage and objectively by downloading the data from a micro sensor chip embedded in the device.